Why Lundbeck’s anti-PACAP migraine drug could matter beyond another Phase II win
Find out how Lundbeck’s bocunebart Phase IIb data could reshape migraine prevention and test the PACAP pathway.
Why Lundbeck’s INFUSE study could broaden how migraine treatment success is measured
Lundbeck’s new Vyepti data highlight migraine-related cognitive symptom gains. Read what the INFUSE study could change for clinicians and the CGRP market.